Senl 006
Alternative Names: Senl_006Latest Information Update: 28 Jun 2023
At a glance
- Originator Hebei Senlang Biotechnology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Glioma in China
- 27 May 2019 Preclinical trials in Glioma in China (unspecified route)